# Ferring to invest CHF 30M in new biotech centre at Saint-Prex, Switzerland

Ferring Pharmaceuticals will invest approximately 30 million CHF over three years to build a new Ferring Biotech Centre at its existing headquarters and manufacturing site in Saint-Prex, Switzerland. The centre will include discovery, development and manufacturing capabilities for biologics and monoclonal antibodies.

- Type: Investment
- Announced: 2018-02-14
- Where: Saint-Prex, Switzerland, Switzerland
- Value: $32.0M (30.0M CHF)
- Status: announced
- Products: biologics, monoclonal antibodies, follitropin delta
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Ferring Pharmaceuticals](https://endata.com/companies/30065.md)

## Sources

- [ferring.com](https://www.ferring.com/ferring-announces-30-million-chf-investment-in-new-biotech-centre-in-switzerland/), 2018-02-14: "Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology and urology."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.